Inventiva S.A. filings document a foreign private issuer and ADR program tied to a clinical-stage biopharmaceutical company developing oral therapies for MASH. Form 6-K reports furnish press releases and meeting notices covering lanifibranor development, annual and preliminary financial results, R&D expense trends, cash resources, revenues, and financing activity.
The company's regulatory disclosures also cover governance and shareholder voting matters, annual general meeting materials, leadership and organizational changes, material agreements, capital-structure disclosures, and portfolio actions including the completed sale of odiparcil. These records connect Inventiva's drug-development focus with its reporting obligations as a France-based issuer listed through American depositary shares.
Inventiva S.A. (IVA) launched a primary offering of 38,961,038 American Depositary Shares at $3.85 per ADS under its shelf registration. The pricing implies a total offering size of $149,999,996, with underwriting commissions of $8,999,999 and estimated net proceeds of approximately $140.1 million. The company also granted underwriters a 30‑day option to purchase up to 5,844,155 additional ADSs at the public offering price, less commissions.
Inventiva plans to use roughly 80% of the proceeds to fund its NATiV3 Phase 3 MASH trial, prepare and initiate an outcomes trial, and support commercialization activities, and about 20% for working capital and general corporate purposes. Ordinary shares outstanding are expected to be 178,112,312 after the offering, or 183,956,467 if the option is fully exercised. The company notes immediate dilution of $3.12 per ADS to new investors.
Inventiva S.A. launched a preliminary prospectus supplement for a $125,000,000 primary offering of American Depositary Shares (ADSs), each representing one ordinary share. The ADSs trade on Nasdaq under “IVA,” and the ordinary shares trade on Euronext Paris as “IVA.”
The company states it will receive the proceeds and has granted underwriters a 30‑day option to purchase additional ADSs. Intended uses include funding the NATiV3 Phase 3 MASH program, preparation/initiation of an outcomes trial, commercialization activities, and general corporate purposes.
As context, cash and cash equivalents were €97.6 million and short‑term deposits were €24.7 million as of September 30, 2025. Ordinary shares outstanding were 139,151,274 as of June 30, 2025, and 146,272,305 as of November 10, 2025. The company discloses it expects to finance activities until the end of Q3 2026 and notes a material uncertainty that may cast significant doubt on its ability to continue as a going concern.
Inventiva S.A. announced its Ordinary and Extraordinary General Meeting, publishing the official notice on November 7, 2025. The meeting will take place on November 27, 2025 at 9 a.m. at Hôtel Villa M, 24-30 boulevard Pasteur, 75015 Paris, France.
The notice of meeting is furnished as Exhibit 99.1 to this Form 6-K and, as stated, is being furnished and not deemed filed under the Exchange Act.
Inventiva S.A. (IVA) announced proxy logistics for its upcoming shareholder meeting. The company began mailing its Proxy Card and Voting Instructions to beneficial owners of its American Depositary Shares in connection with its Ordinary and Extraordinary General Meeting to be held on November 27, 2025 at 9 a.m. at Hôtel Villa M, 24-30 boulevard Pasteur, 75015 Paris, France.
The materials are furnished on a Form 6-K with exhibits: 99.1 (Proxy Card) and 99.2 (Voting Instructions).
Inventiva S.A. announced its Ordinary and Extraordinary General Meeting. The meeting will be held on November 27, 2025 at 9 a.m. at Hôtel Villa M, 24-30 boulevard Pasteur, 75015 Paris, France.
The company published the notice of meeting and furnished it as Exhibit 99.1 to a Form 6-K. The Form 6-K states the information is being furnished, not filed, and that Inventiva files annual reports under cover of Form 20-F.
Inventiva S.A. submitted a Form 6-K announcing two exhibits dated October 14, 2025. The company furnished a press release as Exhibit 99.1 and made available management’s report related to previously disclosed financial statements for the six months ended June 30, 2025 as Exhibit 99.2.
Exhibit 99.1 is furnished and not deemed filed under the Exchange Act. Exhibit 99.2 is incorporated by reference into Inventiva’s Form F-3 (File No. 333-290863) and becomes part of that registration statement from the filing date, unless later superseded.
Inventiva S.A. filed a Form 6-K as a foreign private issuer to provide investors with two key documents for the first half of 2025. The company furnished its Interim Financial Report for the six months ended June 30, 2025 as Exhibit 99.1 and a press release dated September 29, 2025 reporting unaudited first-half 2025 financial results and a corporate update as Exhibit 99.2. The filing is an information update and does not itself describe specific financial figures or major transactions.